Product
Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes
1 clinical trial
2 indications
Indication
Bladder CancerClinical trial
Phase 1 Clinical Trial of Intravesical Adoptive Cell Therapy {ACT) With Tumor Infiltrating Lymphocytes (TIL) for Patients With BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer (NMIBC)Status: Recruiting, Estimated PCD: 2024-11-01